Diagnosis and classification of immune-mediated thrombocytopenia

Ernest Lo, Sean Deane

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Immune thrombocytopenia, or ITP, has been recognized as a clinical entity for centuries, and the importance of humoral mechanisms in the pathophysiology of ITP has been recognized for decades. Despite the long history of the syndrome, progress in understanding its epidemiology and management has been hindered by inconsistencies in nomenclature and classification schema together with the inherent heterogeneity in characteristics of global populations and ITP-associated disorders. In the past decade, great strides have been made in devising a common language for caregivers and investigators alike through standardization definitions and outcome measures, while new tools have become available for management of its clinical manifestations. In 2009, an International Working Group presented proposed standards for definitions, classification criteria, and outcome measures. The American Society of Hematology adopted these standards in 2011, including them in that body's guideline for immune thrombocytopenia. Despite the progress made so far, 20th century interventions such as corticosteroids and IVIg remain the mainstay of therapy. However, advances in treatment have led to the introduction of targeted therapies for select patients with chronic disease. In this paper, we review aspects of the epidemiology and pathophysiology of ITP and discuss the recent changes in guidelines for nomenclature, diagnosis, and treatment.

Original languageEnglish (US)
Pages (from-to)577-583
Number of pages7
JournalAutoimmunity Reviews
Volume13
Issue number4-5
DOIs
StatePublished - 2014

Fingerprint

Inosine Triphosphate
Idiopathic Thrombocytopenic Purpura
Terminology
Epidemiology
Outcome Assessment (Health Care)
Guidelines
Population Characteristics
Therapeutics
Caregivers
Adrenal Cortex Hormones
Chronic Disease
Language
History
Research Personnel

Keywords

  • Autoimmune thrombocytopenia
  • Eltrombopag
  • Idiopathic thrombocytopenic purpura
  • Immune thrombocytopenia
  • Immune thrombocytopenic purpura
  • Romiplostim

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Diagnosis and classification of immune-mediated thrombocytopenia. / Lo, Ernest; Deane, Sean.

In: Autoimmunity Reviews, Vol. 13, No. 4-5, 2014, p. 577-583.

Research output: Contribution to journalArticle

Lo, Ernest ; Deane, Sean. / Diagnosis and classification of immune-mediated thrombocytopenia. In: Autoimmunity Reviews. 2014 ; Vol. 13, No. 4-5. pp. 577-583.
@article{f975ef3074b24a6eae0f1a6fa4495cf7,
title = "Diagnosis and classification of immune-mediated thrombocytopenia",
abstract = "Immune thrombocytopenia, or ITP, has been recognized as a clinical entity for centuries, and the importance of humoral mechanisms in the pathophysiology of ITP has been recognized for decades. Despite the long history of the syndrome, progress in understanding its epidemiology and management has been hindered by inconsistencies in nomenclature and classification schema together with the inherent heterogeneity in characteristics of global populations and ITP-associated disorders. In the past decade, great strides have been made in devising a common language for caregivers and investigators alike through standardization definitions and outcome measures, while new tools have become available for management of its clinical manifestations. In 2009, an International Working Group presented proposed standards for definitions, classification criteria, and outcome measures. The American Society of Hematology adopted these standards in 2011, including them in that body's guideline for immune thrombocytopenia. Despite the progress made so far, 20th century interventions such as corticosteroids and IVIg remain the mainstay of therapy. However, advances in treatment have led to the introduction of targeted therapies for select patients with chronic disease. In this paper, we review aspects of the epidemiology and pathophysiology of ITP and discuss the recent changes in guidelines for nomenclature, diagnosis, and treatment.",
keywords = "Autoimmune thrombocytopenia, Eltrombopag, Idiopathic thrombocytopenic purpura, Immune thrombocytopenia, Immune thrombocytopenic purpura, Romiplostim",
author = "Ernest Lo and Sean Deane",
year = "2014",
doi = "10.1016/j.autrev.2014.01.026",
language = "English (US)",
volume = "13",
pages = "577--583",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "4-5",

}

TY - JOUR

T1 - Diagnosis and classification of immune-mediated thrombocytopenia

AU - Lo, Ernest

AU - Deane, Sean

PY - 2014

Y1 - 2014

N2 - Immune thrombocytopenia, or ITP, has been recognized as a clinical entity for centuries, and the importance of humoral mechanisms in the pathophysiology of ITP has been recognized for decades. Despite the long history of the syndrome, progress in understanding its epidemiology and management has been hindered by inconsistencies in nomenclature and classification schema together with the inherent heterogeneity in characteristics of global populations and ITP-associated disorders. In the past decade, great strides have been made in devising a common language for caregivers and investigators alike through standardization definitions and outcome measures, while new tools have become available for management of its clinical manifestations. In 2009, an International Working Group presented proposed standards for definitions, classification criteria, and outcome measures. The American Society of Hematology adopted these standards in 2011, including them in that body's guideline for immune thrombocytopenia. Despite the progress made so far, 20th century interventions such as corticosteroids and IVIg remain the mainstay of therapy. However, advances in treatment have led to the introduction of targeted therapies for select patients with chronic disease. In this paper, we review aspects of the epidemiology and pathophysiology of ITP and discuss the recent changes in guidelines for nomenclature, diagnosis, and treatment.

AB - Immune thrombocytopenia, or ITP, has been recognized as a clinical entity for centuries, and the importance of humoral mechanisms in the pathophysiology of ITP has been recognized for decades. Despite the long history of the syndrome, progress in understanding its epidemiology and management has been hindered by inconsistencies in nomenclature and classification schema together with the inherent heterogeneity in characteristics of global populations and ITP-associated disorders. In the past decade, great strides have been made in devising a common language for caregivers and investigators alike through standardization definitions and outcome measures, while new tools have become available for management of its clinical manifestations. In 2009, an International Working Group presented proposed standards for definitions, classification criteria, and outcome measures. The American Society of Hematology adopted these standards in 2011, including them in that body's guideline for immune thrombocytopenia. Despite the progress made so far, 20th century interventions such as corticosteroids and IVIg remain the mainstay of therapy. However, advances in treatment have led to the introduction of targeted therapies for select patients with chronic disease. In this paper, we review aspects of the epidemiology and pathophysiology of ITP and discuss the recent changes in guidelines for nomenclature, diagnosis, and treatment.

KW - Autoimmune thrombocytopenia

KW - Eltrombopag

KW - Idiopathic thrombocytopenic purpura

KW - Immune thrombocytopenia

KW - Immune thrombocytopenic purpura

KW - Romiplostim

UR - http://www.scopus.com/inward/record.url?scp=84896319333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896319333&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2014.01.026

DO - 10.1016/j.autrev.2014.01.026

M3 - Article

C2 - 24444701

AN - SCOPUS:84896319333

VL - 13

SP - 577

EP - 583

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 4-5

ER -